Developing a nanoparticle-delivered gene therapy for blinding eye disease
Ophthalmology and engineering combine in a novel nanoparticle-delivered gene therapy approach to treating wet age-related macular degeneration.
List view / Grid view
Ophthalmology and engineering combine in a novel nanoparticle-delivered gene therapy approach to treating wet age-related macular degeneration.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.
Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.